GMGero Massenkeil

Gero Massenkeil

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gero Massenkeil has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • B Dörken

    Department of Haematology and Oncology, Campus Virchow-Klinikum, Charité – University Medicine Berlin, Berlin, Germany

    2 shared publications
  • R Arnold

    Department of Haematology and Oncology, Campus Virchow-Klinikum, Charité – University Medicine Berlin, Berlin, Germany

    2 shared publications
  • A Wille

    Clinic of Urology, Campus Virchow-Klinikum, University Hospital Charité, Berlin, Germany

    1 shared publication
  • A. Kretzschmar

    Charité, Campus Virchow-Klinikum, Berlin, Germany; Robert-Rössle-Klinik, HELIOS-Kliniken Berlin-Buch, Charité Berlin, Germany

    1 shared publication
  • A. Loew

    Charité, Campus Virchow-Klinikum, Berlin, Germany; Robert-Rössle-Klinik, HELIOS-Kliniken Berlin-Buch, Charité Berlin, Germany

    1 shared publication
  • B. Dörken

    Charité, Campus Virchow-Klinikum, Berlin, Germany; Robert-Rössle-Klinik, HELIOS-Kliniken Berlin-Buch, Charité Berlin, Germany

    1 shared publication

Latest Publications

  • Open Access

    Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias

    by G Massenkeil, M Nagy, S Neuburger, I Tamm, C Lutz, P le Coutre, O Rosen, K-D Wernecke, B Dörken, R Arnold

    To assess the role of allogeneic stem cell transplantation (SCT) after reduced-intensity conditioning (RIC) in acute leukaemias, we retrospectively compared 25 patients with acute lymphoblastic leukaemia or acute myelogenous leukaemia after RIC to a historical group of 50 matched controls after high-dose conditioning. Engraftment, acute GvHD and severe infections were comparable in both groups. During the observation period, 1/25 patients (4%) after RIC and 14/50 (28%) after standard SCT died due to transplant-related causes; cumulative nonrelapse mortality (NRM) was 4% after RIC and 24% after standard SCT (P=0.029). In total, 15/25 patients (60%) relapsed after RIC and 20/50 (40%) after standard SCT; probability of disease-free survival (DFS) at 3 years was 43% after RIC and 49% after standard SCT (NS). Overall survival (OS) was 40% after RIC and 37% after standard SCT (NS). Stage of disease, cytogenetic risk profile, acute and chronic GvHD, chimerism status at day 90 and severe infections after transplantation were risk factors with significant impact on DFS and/or OS. In retrospective analysis, patients with acute leukaemias who receive RIC because of contraindications against standard SCT have a comparable outcome to standard SCT, but the higher relapse rate warrants further studies.


  • Capecitabine and docetaxel in advanced gastric adenocarcinoma, an ongoing phase II study

    by P. C. Thuss-Patience, A. Kretzschmar, A. Loew, G. Massenkeil, D. Pink, B. Lebedinzew, S. Micheel, B. Dörken, P. Reichardt

    4224 Background: Docetaxel shows promising activity as single agent and in chemotherapy combination regimens against gastric cancer. In a randomized phase II study it has been shown that a dual combination of docetaxel and continuous infusion 5-FU compared to the reference arm Epirubicin, Cisplatin and 5-FU (ECF) is a well tolerated and very active regimen (Thuss-Patience et al. JCO 2005). In this study we replace the 5-FU infusion with oral fluoropyrimidines and evaluate the efficacy of the dual combination docetaxel and capecitabine (CapDoc). Here we report a preliminary analysis of this ongoing prospective multicenter phase II trial. Methods: Eligibility: Metastatic or locally advanced gastro-esophageal-junction or gastric adenocarcinoma, ECOG PS 0–2, no prior palliative chemotherapy. Chemotherapy: Docetaxel 75 mg/m2 d1, Capecitabine 2000 mg/m2 d1–14, q3w. Results: 17 patients (pts) are included in this ongoing trial. Age: 32–79 yrs (median 60), M/F 4/13, ECOG PS 0: 4 pts, 1: 11 pts, 2: 2 pts. Number of organs involved by metastases: 1: 2 pts, 2: 6 pts, 3: 5 pts, 4: 3pts, 5: 1 pt. Measurable disease (RECIST): 17 pts. 59 cycles of chemotherapy are administered so far. Toxicity: 13 pts are evaluable for toxicity (worst grade per patient/% of pts): Grade 1/2/3/4: Nausea: 38%/8%/-/-/, vomiting: 8%/23%/-/-/, diarrhea: 23%/23%/-/-/, asthenia: 38%/31%/-/-/, stomatitis: 8%/15%/ 8%/-/, alopecia: 62%/23%/-/-/, fever not neutropenic: 8%/23%/-/-/, neutropenic fever: -/-/8%/-/, nail changes: 15%/15%/-/-/, atrial fibrillation: -/-/15%/-/, paresthesia: 15%/8%/-/-/, dizziness: 15%/8%/15%/-/, hand-foot-syndrome: 15%/8%/23%/-/, leuko-neutropenia: -/-/23%/31%, thrombocytopenia: 8%/-/-/-/, anemia: 8%/8%/8%/-/, fluid retention: 23%/-/-/-/, pulmonary embolism: -/8%/-/8%. Response: 11 pts are so far evaluable for response: CR 1 pt, PR 5 pts, NC 5 pts, PD 0 pts, (objective response rate: 55%). So far no patient showed primary resistance to CapDoc. Conclusion: These preliminary data suggest that CapDoc is a well tolerated combination with very promising efficacy in gastric cancer.


  • Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity

    by G Massenkeil, J Roigas, M Nagy, A Wille, C Stroszczynski, M Y Mapara, S Loening, B Dörken, R Arnold

    Seven out of 29 patients with metastatic renal cell carcinoma (RCC) considered eligible for allogeneic stem cell transplantation underwent nonmyeloablative stem cell transplantation (NST) from HLA-identical donors. Conditioning comprised cyclophosphamide, fludarabine and antithymocyte globulin. Prolonged mixed chimerism (MC) after engraftment converted to complete donor chimerism (CC) after infusion of donor lymphocytes and/or graft-versus-host disease (GvHD) in six patients. Five patients developed severe GvHD. Two of seven patients had a delayed tumor response after conversion to CC. After a median follow-up of 10 months (4–24 months), 5/7 patients are alive, one in very good partial remission (PR), one with stable and three with progressive disease. One of the seven patients died from sepsis in PR and 1/7 died from rapid tumor progression after sustained MC. None of the 22 nontransplanted patients responded to further therapies. Survival after 1 year was 59% in transplanted and 66% in nontransplanted patients (n.s.). A pooled data analysis from the literature suggests a graft-versus-tumor effect after transplant in patients with metastatic RCC, which becomes effective after chimerism conversion. Available data demonstrate high nonrelapse mortality in these patients. NST in RCC still has to be regarded as an investigational approach requiring careful patients' selection and longer follow-up within clinical studies.


  • Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD

    by Gero Massenkeil, Marion Nagy, Philipp le Coutre, Felicitas Heine, Oliver Rosen, Berud Dörken, Renate Arnold